More Alberta seniors are now eligible for provincially funded RSV vaccines. All Albertans 70 and over are now eligible.

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.

identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this PreF protein, as do other candidates in the late-stage ...

Investigators randomly assigned participants in the United States and Japan in a 1:1 ratio to receive one dose of Pfizer’s bivalent (two-strain) RSV Prefusion F (RSVpreF) vaccine (Abrysvo ...

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

in infants—the RSV prefusion F (RSVpreF; ABRYSVO) vaccine for pregnant individuals and the monoclonal antibody nirsevimab (Beyfortus) for newborns—has shown high uptake in a recent cohort study.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...

The CDC encourages doctors to vaccinate babies and adults over 60 years old, with two RSV vaccines for seniors, GSK’s Arexvy (88% effective) and Pfizer’s Abrysvo(85% effective), currently ...

The UK government recently launched a national vaccination programme to protect infants and older adults against RSV with Pfizer’s Abrysvo. The new initiative, which launched in September, includes a ...

Despite 50 years of research, there are currently no RSV vaccines approved or in Phase III trials for any of the target populations. High levels of neutralizing antibodies to RSV F protein have ...